Psyched Wellness Receives DTC EligibilityCybin Advances IND-Enabling Studies of Two Psychedelic Molecules, CYB003 and CYB004 for Investigational New Drug ApplicaRritual Appoints Sarton Molnar-Fenton, Vice President Sales USATryp Therapeutics Announces Listing on OTCQB and DTC EligibilityPure Extracts Dual Vertical Approach Incorporating Cannabis and Psychedelic Compounds Is Starting To Pay OffTryp Therapeutics Appoints Greg McKee as Chief Executive OfficerPsyence Group and Pure Extracts Sign JV Letter of Intent for the Extraction of Psilocybin from Psychedelic Mushrooms andCybin Announces Senior Management Changes to Lead Buildout of Development and Clinical Capabilities in the United StatesPsyched Wellness Initiates Study on AME-1 Extract for Gut HealthRritual Superfoods to Launch Product Line in Rite Aid Stores – NationwideMushroomStocks.com Deep Dive: Tryp Therapeutics (CSE:TRYP)Cybin Signs Drug Development Agreement with Catalent for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (Field Trip Has A Warchest Of Cash To Propel R&D and M&A Moving ForwardCybin Inc. Is Rapidly Progressing Its Drug Development Program With Plenty On The HorizonPure Extracts Orders Cutting Edge Vitalis Cosolvent Injection SystemTryp Therapeutics Announces Provisional Patent Filing For Improved Administration of PsychedelicsCybin Progresses Two Psychedelic Investigational New Drug (“IND”) Candidates and Announces Completion of Its 20th PrRritual Announces Successful Completion of Second Full Scale Manufacturing Run and Commencement of Third Full Scale ManuNuminus Wellness Is Taking Strides To Advance Its R&D Business UnitRritual Announces Successful Launch of US Facing E-Commerce Website and Provides Corporate Update
Back

Field Trip Has A Warchest Of Cash To Propel R&D and M&A Moving Forward

Mar 22, 2021 • 7:30 AM EDT
2 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

If you have not been following Field Trip Health Ltd. (CSE: FTRP) (OTCQX: FTRPF), you may want to put the company on your radar after it closed a massive private placement.

Last week, Field Trip reported to have closed a previously announced $95 million bought deal short form prospectus offering. The financing included the full exercise of the underwriters’ over-allotment option and we consider this to be a positive for the company.

Field Trip is considered to be a leader in the development and delivery of psychedelic therapies, and we are excited to see how the management team uses the proceeds to advance the business.

Field Trip CEO Joseph del Moral stated that the closing of the financing is an important milestone for the business as it provides the resources that are needed to execute on previously announced initiatives. We believe the size of the financing is a testament to the strength of the platform and will closely monitor the business on a going forward basis.

Soleus Capital Management was the lead investor in the financing, and we believe that Field Trip is backed by smart money. The firm stated that it believes that Field Trip is positioned to establish itself as a global leader in the delivery and development of psychedelic therapies for depression and other mental health indications with high unmet need.

We are favorable on the size of the total addressable market (TAM) of the indications that Field Trip is focused on. The company plans to use the proceeds from the financing for the ongoing development of the “FT-104” novel psychedelic development program, the opening of new Field Trip Health centers, and for working capital and general corporate purposes.

Going forward, we expect Field Trip to accelerate the rollout of its branded health centers across North America and Europe. The company has the proceeds to fund this initiative and will still have enough resources to capitalize on unique and accretive growth opportunities.

We believe that Field Trip has been nothing short of an execution story and will monitor how the story advances from here. If you are interested in learning more about Field Trip Health, please send an email to support@mushroomstocks.com with the subject “Field Trip Health” to be added to our distribution list.

For the fastest access to data on Field Trip Health, you can set up a free account or sign up for our free newsletter!

Share Share - Facebook Share - Twitter

Tags

Authored By

Michael Berger

Comments

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link